(Q37550525)

21 August 2017

1 reference

title

Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension (English)

1 reference

21 August 2017

main subject

arterial hypertension

0 references

3

Fernando Torres

1 reference

21 August 2017

Martha Kingman

1

1 reference

21 August 2017

Rosechelle Ruggiero

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1847-1858

1 reference

Epidemiology of pulmonary arterial hypertension

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Clinical significance of brain natriuretic peptide in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Ambrisentan for the management of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903061275

10.1517/14656560903061275

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference